Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease

University of California San Diego (UCSD) Health is the initial and lead center for the Phase 1 clinical trial under the leadership of Eric Adler, M.D., Director of The post Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease appeared first on Pharmaceutical Business review.

Novo Nordisk’s Victoza secures FDA paediatric approval for type 2 diabetes

Victoza was approved by the regulator for the treatment of type 2 diabetes in adult patients in 2010. It is now the first non-insulin drug to be approved The post Novo Nordisk’s Victoza secures FDA paediatric approval for type 2 diabetes appeared first on Pharmaceutical Business review.

AstraZeneca, Merck get EC nod for Lynparza to treat advanced ovarian cancer

With the approval, Lynparza can be used as a maintenance treatment for adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, The post AstraZeneca, Merck get EC nod for Lynparza to treat advanced ovarian cancer appeared first on Pharmaceutical Business review.

Roche gets Japanese approval for personalised medicine Rozlytrek

Rozlytrek is the first tumour-agnostic medicine to be approved in Japan that targets NTRK gene fusions, which have been identified in a range of hard-to-treat solid tumour types, The post Roche gets Japanese approval for personalised medicine Rozlytrek appeared first on Pharmaceutical Business review.

Mycovia, Jiangsu Hengrui to develop and commercialize antifungal therapy VT-1161

RVVC is also known as chronic yeast infection and is often accompanied by severe physical discomfort and emotional burden. Mycovia is currently conducting global Phase 3 trials of The post Mycovia, Jiangsu Hengrui to develop and commercialize antifungal therapy VT-1161 appeared first on Pharmaceutical Business review.

Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody

The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal The post Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody appeared first on Pharmaceutical Business review.

Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials

Guselkumab, which was subcutaneously injected in the participating patients, was assessed for its efficacy and safety in the DISCOVER 1 and 2 trials compared to placebo. Janssen said The post Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials appeared first on Pharmaceutical Business review.

Pfizer to buy Array BioPharma for £9.06bn

Array BioPharma is involved in the discovery, development and commercialisation of targeted small molecule medicines for the treatment of cancer and other high-burden diseases. The company sells Braftovi The post Pfizer to buy Array BioPharma for £9.06bn appeared first on Pharmaceutical Business review.

Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria

Sustained efficacy of ULTOMIRIS was observed on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels and the secondary endpoints of LDH level reduction The post Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria appeared first on Pharmaceutical Business review.

Dr. Reddy’s to sell neurology branded products to Upsher-Smith Laboratories

Under the agreement, Dr. Reddy’s will receive U.S.$70 million as upfront consideration, U.S.$40.5 million in near term milestones and additional financial considerations including existing contractual obligation and inventory. The post Dr. Reddy’s to sell neurology branded products to Upsher-Smith Laboratories appeared first on Pharmaceutical Business review.